229 related articles for article (PubMed ID: 25922341)
1. DSR-71167, a novel mineralocorticoid receptor antagonist with carbonic anhydrase inhibitory activity, separates urinary sodium excretion and serum potassium elevation in rats.
Nariai T; Fujita K; Kawane K; Mori M; Nakayama R; Matsuda K; Katayama S; Fukuda N; Hori S; Iwata M; Hasegawa F; Suzuki K; Kato H
J Pharmacol Exp Ther; 2015 Jul; 354(1):2-9. PubMed ID: 25922341
[TBL] [Abstract][Full Text] [Related]
2. SM-368229, a novel selective and potent non-steroidal mineralocorticoid receptor antagonist with strong urinary Na+ excretion activity.
Nariai T; Fujita K; Mori M; Katayama S; Hori S; Matsui K
J Pharmacol Sci; 2011; 115(3):346-53. PubMed ID: 21358118
[TBL] [Abstract][Full Text] [Related]
3. SM-368229, a novel promising mineralocorticoid receptor antagonist, shows antihypertensive efficacy with minimal effect on serum potassium level in rats.
Nariai T; Fujita K; Mori M; Katayama S; Hori S; Matsui K
J Cardiovasc Pharmacol; 2012 May; 59(5):458-64. PubMed ID: 22240917
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist.
Arai K; Homma T; Morikawa Y; Ubukata N; Tsuruoka H; Aoki K; Ishikawa H; Mizuno M; Sada T
Eur J Pharmacol; 2015 Aug; 761():226-34. PubMed ID: 26073023
[TBL] [Abstract][Full Text] [Related]
5. Preclinical pharmacology of AZD9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion.
Bamberg K; Johansson U; Edman K; William-Olsson L; Myhre S; Gunnarsson A; Geschwindner S; Aagaard A; Björnson Granqvist A; Jaisser F; Huang Y; Granberg KL; Jansson-Löfmark R; Hartleib-Geschwindner J
PLoS One; 2018; 13(2):e0193380. PubMed ID: 29474466
[TBL] [Abstract][Full Text] [Related]
6. CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats.
Arai K; Tsuruoka H; Homma T
Eur J Pharmacol; 2015 Dec; 769():266-73. PubMed ID: 26607463
[TBL] [Abstract][Full Text] [Related]
7. Antihypertensive and cardiorenal protective effects of SM-368229, a novel mineralocorticoid receptor antagonist, in aldosterone/salt-treated rats.
Nariai T; Fujita K; Mori M; Katayama S; Hori S; Matsui K
Pharmacology; 2012; 89(1-2):44-52. PubMed ID: 22302095
[TBL] [Abstract][Full Text] [Related]
8. Mineralocorticoid receptor activation contributes to salt-induced hypertension and renal injury in prepubertal Dahl salt-sensitive rats.
Kawarazaki H; Ando K; Nagae A; Fujita M; Matsui H; Fujita T
Nephrol Dial Transplant; 2010 Sep; 25(9):2879-89. PubMed ID: 20466668
[TBL] [Abstract][Full Text] [Related]
9. Development of a simplified assay for determination of the antimineralocorticoid activity of compounds dosed in rats.
Brandish PE; Chen H; Szczerba P; Hershey JC
J Pharmacol Toxicol Methods; 2008; 57(2):155-60. PubMed ID: 18304838
[TBL] [Abstract][Full Text] [Related]
10. The use of plasma aldosterone and urinary sodium to potassium ratio as translatable quantitative biomarkers of mineralocorticoid receptor antagonism.
Eudy RJ; Sahasrabudhe V; Sweeney K; Tugnait M; King-Ahmad A; Near K; Loria P; Banker ME; Piotrowski DW; Boustany-Kari CM
J Transl Med; 2011 Oct; 9():180. PubMed ID: 22017794
[TBL] [Abstract][Full Text] [Related]
11. Role of mineralocorticoid receptor on atrial structural remodeling and inducibility of atrial fibrillation in hypertensive rats.
Kimura S; Ito M; Tomita M; Hoyano M; Obata H; Ding L; Chinushi M; Hanawa H; Kodama M; Aizawa Y
Hypertens Res; 2011 May; 34(5):584-91. PubMed ID: 21248754
[TBL] [Abstract][Full Text] [Related]
12. Mineralocorticoid receptor blockade and calcium channel blockade have different renoprotective effects on glomerular and interstitial injury in rats.
Du J; Fan YY; Hitomi H; Kiyomoto H; Kimura S; Kong CZ; Noma T; Kohno M; Nishiyama A; Nakano D
Am J Physiol Renal Physiol; 2009 Sep; 297(3):F802-8. PubMed ID: 19535572
[TBL] [Abstract][Full Text] [Related]
13. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential.
Fuhrmann U; Krattenmacher R; Slater EP; Fritzemeier KH
Contraception; 1996 Oct; 54(4):243-51. PubMed ID: 8922878
[TBL] [Abstract][Full Text] [Related]
14. Discovery of 6-[5-(4-fluorophenyl)-3-methyl-pyrazol-4-yl]-benzoxazin-3-one derivatives as novel selective nonsteroidal mineralocorticoid receptor antagonists.
Hasui T; Ohyabu N; Ohra T; Fuji K; Sugimoto T; Fujimoto J; Asano K; Oosawa M; Shiotani S; Nishigaki N; Kusumoto K; Matsui H; Mizukami A; Habuka N; Sogabe S; Endo S; Ono M; Siedem CS; Tang TP; Gauthier C; De Meese LA; Boyd SA; Fukumoto S
Bioorg Med Chem; 2014 Oct; 22(19):5428-45. PubMed ID: 25187277
[TBL] [Abstract][Full Text] [Related]
15. Mineralocorticoid receptors/epithelial Na(+) channels in the choroid plexus are involved in hypertensive mechanisms in stroke-prone spontaneously hypertensive rats.
Nakano M; Hirooka Y; Matsukawa R; Ito K; Sunagawa K
Hypertens Res; 2013 Mar; 36(3):277-84. PubMed ID: 23096235
[TBL] [Abstract][Full Text] [Related]
16. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
Moore TD; Nawarskas JJ; Anderson JR
Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
[TBL] [Abstract][Full Text] [Related]
17. Eplerenone potentiates protective effects of amlodipine against cardiovascular injury in salt-sensitive hypertensive rats.
Nakamura T; Fukuda M; Kataoka K; Nako H; Tokutomi Y; Dong YF; Yamamoto E; Yasuda O; Ogawa H; Kim-Mitsuyama S
Hypertens Res; 2011 Jul; 34(7):817-24. PubMed ID: 21471977
[TBL] [Abstract][Full Text] [Related]
18. Differences in the determinants of eplerenone, spironolactone and aldosterone binding to the mineralocorticoid receptor.
Rogerson FM; Yao Y; Smith BJ; Fuller PJ
Clin Exp Pharmacol Physiol; 2004 Oct; 31(10):704-9. PubMed ID: 15554912
[TBL] [Abstract][Full Text] [Related]
19. Paradoxical mineralocorticoid receptor activation and left ventricular diastolic dysfunction under high oxidative stress conditions.
Wang H; Shimosawa T; Matsui H; Kaneko T; Ogura S; Uetake Y; Takenaka K; Yatomi Y; Fujita T
J Hypertens; 2008 Jul; 26(7):1453-62. PubMed ID: 18551023
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of mineralocorticoid receptors with eplerenone alleviates short-term cyclosporin A nephrotoxicity in conscious rats.
Nielsen FT; Jensen BL; Marcussen N; Skøtt O; Bie P
Nephrol Dial Transplant; 2008 Sep; 23(9):2777-83. PubMed ID: 18424460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
